Literature DB >> 25954926

Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barré syndrome.

Yamei Du1, Guojun Zhang1, Zaiqiang Zhang2, Qian Wang1, Ruimin Ma1, Limin Zhang1, Fei Fan1, Youran Li1, Meng Wang1, Hong Lv1, Xixiong Kang1.   

Abstract

Guillain-Barré syndrome (GBS) is an autoimmune disorder of the peripheral nervous system characterized by weakness in the limbs. To date, numerous hypotheses have been suggested to explain the pathogenesis of GBS; however, the pathogenesis of GBS remains to be elucidated. The aim of the present study was to investigate the association between Toll-like receptor (TLR) 2, TLR4 and GBS. Therefore, the mRNA of TLR2, TLR4, myeloid differentiation factor (MyD)88 and nuclear factor (NF)-κB of peripheral blood mononuclear cells (PBMCs) in patients with GBS and healthy controls was assessed. To confirm the function of TLR2 and TLR4 in the pathogenesis of GBS, PBMCs derived from patients with GBS and healthy controls were cultured with various TLR agonists. The levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β were measured in the culture supernatant and fasting serum was obtained for the detection of anti-ganglioside antibodies. The results revealed that the mRNA levels of TLR2, TLR4, MyD88 and NF-κB were significantly increased in patients with GBS compared with those in healthy controls (P=0.003, 0.017, 0.032 and 0.015, respectively). PBMCs from patients with GBS secreted higher levels of TNF-α and IL-1β than those from control subjects. The positive rate of immunoglobulin (Ig)G and IgM anti-ganglioside antibodies in patients with severe GBS was 42.86%, which was markedly higher than rates found in patients with mild GBS (9.09 and 18.18%, respectively). The results of the present study demonstrated that TLR2 and TLR4 are involved in the pathogenesis of GBS and that they and their associated signaling pathways may be targets for the treatment of GBS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25954926     DOI: 10.3892/mmr.2015.3730

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

Review 1.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

2.  Association of anti-gangliosides antibodies and anti-CMV antibodies in Guillain-Barré syndrome.

Authors:  Lijuan Wang; Chunqing Shao; Chunjiao Yang; Xixiong Kang; Guojun Zhang
Journal:  Brain Behav       Date:  2017-04-07       Impact factor: 2.708

3.  Fulminant Guillain-Barré Syndrome and Spontaneous Intraventricular Hemorrhage: A Case Report and Literature Review.

Authors:  Jun Hu; Xiaoqian Luo; Yu Wang; Eric Prado; Qinghui Fu; Anwen Shao
Journal:  Front Neurosci       Date:  2020-06-30       Impact factor: 4.677

4.  Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy.

Authors:  Oladayo Oladiran; Xiang Qun Shi; Mu Yang; Sylvie Fournier; Ji Zhang
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 5.  Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.

Authors:  Haixia Li; Shan Liu; Jinming Han; Shengxian Li; Xiaoyan Gao; Meng Wang; Jie Zhu; Tao Jin
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

6.  Remnant Cholesterol and Dyslipidemia Are Risk Factors for Guillain-Barré Syndrome and Severe Guillain-Barré Syndrome by Promoting Monocyte Activation.

Authors:  Yaowei Ding; Lijuan Wang; Jialu Sun; Yijun Shi; Guoge Li; Xin Luan; Guanghui Zheng; Guojun Zhang
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

7.  Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells.

Authors:  Thomas Grüter; Alina Blusch; Jeremias Motte; Melissa Sgodzai; Hussein Bachir; Rafael Klimas; Björn Ambrosius; Ralf Gold; Gisa Ellrichmann; Kalliopi Pitarokoili
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.